A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)

Clinical trial NCT05267470 · TERMINATED

Trial details

NCT number: NCT05267470
Sponsor: Amgen
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Squamous-Cell Non-Small-Cell Lung Cancer

Start date: 2022-03-29
Primary completion: 2024-05-28
Enrollment: 74

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.